• Preclinical study demonstrates NYR-BI03 provides strong cardioprotection when administered as a short-duration intravenous infusion following myocardial infarction
• Significant reductions in both heart muscle injury size and Troponin I, a key cardiac injury biomarker
• NYR-BI03 treated animals displayed reduced incidence of ventricular arrhythmias, the leading cause of sudden cardiac death following heart attack

Nyrada Inc. (ASX:NYR), a drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) channel inhibitors, today announces the results of a preclinical cardiac arrhythmia study. Utilizing the same rodent model from Nyrada's October 2024 study but conducted by a different contract research organisation (CRO), subject animals were administered NYR-BI03 at doses of 3.0 and 9.0 mg/kg over 3 hours following acute myocardial ischemia (AMI). The study demonstrated that NYR-BI03 provided a dose-dependent reduction in the size of heart muscle injury, with a statistically significant 42% reduction at the 9 mg/kg dose compared to vehicle. NYR-BI03 also showed a dose-dependent reduction in Troponin I, a key cardiac injury biomarker, with a statistically significant 32% reduction at the 9 mg/kg dose. Additionally, animals treated with NYR-BI03 displayed a statistically significant reduction in ventricular premature beats, which can trigger ventricular tachycardia and ventricular fibrillation, the leading causes of sudden cardiac death following a heart attack. The study also found that NYR-BI03 completely suppressed ventricular fibrillation events compared to the vehicle group. These findings further validate the strong cardioprotective efficacy of NYR-BI03 and confirm its anti-arrhythmic effects, positioning it as a promising treatment for AMI-related conditions.

Nyrada CEO James Bonnar commented: 'These findings are very exciting and further validate the strong cardioprotective efficacy of NYR-BI03, as demonstrated in our earlier study. It also confirms NYR-BI03's anti-arrhythmic effects, as seen in a TRPC knockout animal model, validating our approach and highlighting the drug's potential to address multiple risks following a heart attack. NYR-BI03 has now demonstrated preclinical efficacy in three significant indications, ischemic stroke, traumatic brain injury (TBI), and acute myocardial infarction, with our Phase I trial supporting multiple development pathways.'